NASDAQ: BLSMBlossomhill Therapeutics Inc Stock
$19.75-0.72 (-3.52%)
Updated Sep 25, 2026
BLSM Price
$19.75
Fair Value Price
$3.93
Market Cap
$627.75M
52 Week Low
$15.25
52 Week High
$27.99
P/E
N/A
P/B
-3.59x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.24
Operating Cash Flow
N/A
Beta
1.4
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BLSM Overview
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BLSM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BLSM
Ranked#238 of 464
Ranked#238 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.77 | A | |
| $7.75 | A | |
| $360.85 | A |
Be the first to know about important BLSM news, forecast changes, insider trades & much more!
BLSM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BLSM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLSM ($19.75) is overvalued by 402.57% relative to our estimate of its Fair Value price of $3.93 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BLSM ($19.75) is not significantly undervalued (402.57%) relative to our estimate of its Fair Value price of $3.93 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BLSM's short-term assets ($100.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more BLSM due diligence checks available for Premium users.
Valuation
BLSM fair value
Fair Value of BLSM stock based on Discounted Cash Flow (DCF)
Price
$19.75
Fair Value
$3.93
Overvalued by
402.57%
BLSM ($19.75) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BLSM ($19.75) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BLSM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.59x
Industry
5.19x
BLSM's financial health
Profit margin
Revenue
$0.0
Net Income
-$23.8M
Profit Margin
0%
Assets to liabilities
Assets
$124.1M
Liabilities
$42.1M
Debt to equity
-0.24
BLSM's short-term assets ($100.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLSM's short-term assets ($100.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLSM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BLSM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.2M
Investing
$0.0
Financing
$2.6M
BLSM vs Biotech Stocks
Blossomhill Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.